Bladder cancer treatment doubles survival
Patients living with bladder cancer can receive a treatment that can double survival rates from the disease. The treatment which has been approved for use on the NHS has been hailed as one of the most hopeful advances in decades for people with bladder cancer. Around 1,250 patients with bladder cancer in England a year could be offered the therapy, which significantly boosts survival and remission rates. In clinical trials of the drug, people with bladder cancer that had spread (metastasised) lived up to twice as long when given the combination antibody treatment compared to those given normal chemotherapy.